Stay updated on Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Sign up to get notified when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.

Latest updates to the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page
- CheckyesterdayChange DetectedVersion bumped to v3.0.2 from v3.0.1; 'Back to Top' link removed. No substantive content changes.SummaryDifference0.2%
- Check8 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, pricing, or availability.SummaryDifference0.2%
- Check15 days agoChange DetectedThe web page has updated its facility name and location details, specifically adding Milan and Padua, Italy, while removing previous location terms and references to infections and antirheumatic agents.SummaryDifference2%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated to version v2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1.0%
Stay in the know with updates to Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.